Want to see IL:NRGN full AI Analyst Report?
NRGN Stock Chart & Stats
204.80
0.03(0.96%)
At close: 4:00 PM EST
204.80
0.03(0.96%)
Day’s Range― - ―
52-Week Range190.80 - 310.00
Previous CloseN/A
Volume1.26K
Average Volume (3M)27.56K
Market Cap
₪28.52M
Enterprise Value5.76M
Total Cash (Recent Filing)₪5.30M
Total Debt (Recent Filing)₪181.00K
Price to Earnings (P/E)―
Beta0.52
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding13,327,785
10 Day Avg. Volume57,803
30 Day Avg. Volume27,561
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.94
Price to Sales (P/S)2.64
P/FCF Ratio116.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue & Gross‑margin ReboundA powerful top-line inflection and materially better unit economics indicate product traction and improved monetization of the Genomics Suite. Higher gross margins support scalability: if revenue growth holds, incremental sales will more directly flow to operating leverage and faster path to sustained profitability over months.
Conservative LeverageVery low financial leverage gives the company flexibility to fund R&D, absorb operational volatility, and pursue strategic investments without immediate refinancing pressure. This balance sheet conservatism reduces bankruptcy risk and supports multi-month execution on growth initiatives.
Proprietary Software PlatformA focused software and computational biology platform creates durable competitive advantages: repeatable software licensing/subscription revenue, higher gross margins, and switching costs for customers doing complex genome assembly. Combined services revenue fosters stickiness and cross‑sell opportunities.
Bears Say
Large Ongoing LossesDespite revenue recovery, the company remains deeply loss-making, which limits internal funding for growth and increases reliance on external capital. Persistent negative margins depress returns to shareholders and could erode equity over time if losses continue, constraining durable financial resilience.
Fragile Free Cash FlowOperating cash flow turned positive but free cash flow is minimal and volatile, with year-over-year decline. Small, inconsistent FCF limits the firm's ability to self-fund R&D, sales expansion, or buffer setbacks, making sustained growth dependent on improving cash conversion or external financing.
Limited Revenue TransparencyLack of disclosed customer concentration, contract terms, or major partner names reduces visibility into recurring revenue durability and renewal risk. This opacity makes forecasting and assessing sustainable revenue streams harder, raising structural uncertainty about durable demand and contract stickiness.
NRGN FAQ
What was NRGENE TECHNOLOGIES LTD’s price range in the past 12 months?
NRGENE TECHNOLOGIES LTD lowest stock price was 190.80 and its highest was 310.00 in the past 12 months.
What is NRGENE TECHNOLOGIES LTD’s market cap?
NRGENE TECHNOLOGIES LTD’s market cap is ₪28.52M.
When is NRGENE TECHNOLOGIES LTD’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were NRGENE TECHNOLOGIES LTD’s earnings last quarter?
Currently, no data Available
Is NRGENE TECHNOLOGIES LTD overvalued?
According to Wall Street analysts NRGENE TECHNOLOGIES LTD’s price is currently Overvalued.
Does NRGENE TECHNOLOGIES LTD pay dividends?
NRGENE TECHNOLOGIES LTD does not currently pay dividends.
What is NRGENE TECHNOLOGIES LTD’s EPS estimate?
NRGENE TECHNOLOGIES LTD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NRGENE TECHNOLOGIES LTD have?
NRGENE TECHNOLOGIES LTD has 13,327,785 shares outstanding.
What happened to NRGENE TECHNOLOGIES LTD’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NRGENE TECHNOLOGIES LTD?
Currently, no hedge funds are holding shares in IL:NRGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NRGENE TECHNOLOGIES LTD
NRGene Technologies Ltd is an AI-powered genomics firm that designs sophisticated computational tools and advanced algorithms, serving clients globally across North America, Europe, the Middle East, Africa, and Asia Pacific. The company provides specialized software applications and complete, ready-to-use solutions for various sectors, including agricultural breeding, food technology, academia, research institutions, and agribiotech enterprises. Additionally, NRGene develops custom genetic panels tailored for a broad range of plants, from staple crops like wheat, canola, corn, soybeans, and maize to cannabis. Established in 2009, its headquarters are located in Ness Ziona, Israel.